S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

• P. L. Zinzani,
• J. Mayer,
• R. Auer,
• F. Bijou,
• A. C. de Oliveira,
• C. R. Flowers,
• M. Merli,
• K. Bouabdallah,
• P. S. Ganly,
• Y. Song,
• H. Zhang,
• R. Johnson,
• A. M García-Sancho,
• M. Provencio,
• M. Trněný,
• S. Yuen,
• H. Tilly,
• E. Kingsley,
• G. Tuyman,
• S. E. Assouline,
• E. Ivanova,
• P. Kim,
• J. Huang,
• R. Delarue,
• J. Trotman

Affiliations

P. L. Zinzani

1 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy

J. Mayer

2 Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czechia

R. Auer

3 St. Bartholomew’s Hospital, Barts Health NHS Trust, London, United Kingdom

F. Bijou

4 Institut Bergonié, Bordeaux, France

A. C. de Oliveira

5 Institut Catala d’Oncologia (ICO) Hospital Duran I Reynals, Hospital, Barcelona, Spain

C. R. Flowers

6 Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America

M. Merli

7 Hematology, University Hospital “Ospedale di Circolo e Fondazione Macchi” - ASST Sette Laghi, University of Insubria, Varese, Italy

K. Bouabdallah

8 Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France

P. S. Ganly

9 Department of Haematology, Christchurch Hospital, Christchurch, New Zealand

Y. Song

10 Beijing Cancer Hospital, Beijing

H. Zhang

11 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

R. Johnson

12 St. James’s University Hospital Trust, Leeds, United Kingdom

A. M García-Sancho

13 Hospital Universitario de Salamanca, Salamanca

M. Provencio

14 Hospital Universitario Puerta de Hierro — Majadahonda, Madrid, Spain

M. Trněný

15 Vseobecna fakultní nemocnice v Praze, Prague, Czechia

S. Yuen

16 Calvary Mater Newcastle, Waratah, New South Wales, Australia

H. Tilly

17 Centre Henri-Becquerel, Rouen, France

E. Kingsley

18 Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States of America

G. Tuyman

19 Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia

S. E. Assouline

20 Jewish General Hospital, Montreal, Canada

E. Ivanova

21 BeiGene Switzerland GmbH, Basel, Switzerland

P. Kim

22 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

J. Huang

22 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

R. Delarue

21 BeiGene Switzerland GmbH, Basel, Switzerland

J. Trotman

23 Concord Repatriation General Hospital